Biogen raises annual profit forecast on strong demand for rare disease drugs

Biogen raised its 2025 adjusted profit forecast to $15.50-$16.00 per share, up from $14.50-$15.50, citing strong demand for rare disease drugs like Skyclarys, which is offsetting declining sales of its older multiple sclerosis portfolio. The company also reported robust second-quarter adjusted earnings of $5.47 per share, significantly exceeding analyst estimates, and Leqembi sales of $63 million. Shares surged nearly 8% in premarket trading, reflecting investor confidence in Biogen's strategic shift towards newer therapies and its ability to mitigate potential tariff impacts through increased domestic manufacturing.

Analysis

Biogen has demonstrated significant operational momentum by raising its full-year 2025 adjusted profit forecast to a range of $15.50 to $16.00 per share, a notable increase from the previous $14.50 to $15.50. This upward revision is underpinned by robust demand for its rare disease drugs, such as Skyclarys, which are effectively offsetting the secular decline in its legacy multiple sclerosis drug sales. The company's second-quarter performance provides strong validation, with adjusted earnings of $5.47 per share decisively beating the LSEG analyst consensus of $3.86. While the adoption of its Alzheimer's treatment, Leqembi, remains slow, its Q2 sales of $63 million slightly exceeded Wall Street's $60.5 million estimate, offering a marginal positive data point. Furthermore, management has proactively addressed geopolitical risk by stating that potential tariffs are not expected to have a material impact, a position supported by a $2 billion investment to expand its domestic manufacturing footprint in North Carolina. The nearly 8% premarket share price increase reflects strong investor confidence in this strategic pivot and improved financial outlook.

Key Decisions for Investors

• The significant earnings beat and upwardly revised guidance suggest Biogen's profitability is improving faster than anticipated, warranting a reassessment of valuation models to incorporate the higher earnings power.
• Investors should closely monitor the sales ramp of Leqembi in subsequent quarters, as its ability to accelerate beyond the current modest pace is critical to the long-term growth thesis and justifying a higher multiple.
• Given the stated strategy, continue to track the revenue growth from the rare disease portfolio to ensure it provides a sufficient bridge to offset the predictable decline in the multiple sclerosis franchise.
• While the company has signaled confidence in mitigating tariff impacts through domestic manufacturing, positions should still account for headline risk associated with any definitive changes to U.S. trade policy on pharmaceuticals.